Autor(es): Wu Xiujuan,Wang Juan,Liu Kangding,Zhu Jie,Zhang Hong-Liang

Resumo: Guillain-Barré syndrome (GBS) is an immune-mediated inflammatory disorder of the peripheral nervous system (PNS). Experimental autoimmune neuritis (EAN) is a useful animal model for studying GBS. Currently, GBS remains a life-threatening disorder and more effective therapeutic strategies are in urgent need. Accumulating evidence has revealed that T helper (Th) 17 cells and their cytokines are pathogenic in GBS/EAN. Drugs attenuated clinical signs of GBS/EAN, in part, by decreasing Th17 cells or IL-17A. Th17 cells and their cytokines might be potential therapeutic targets. Approaches targeting Th17 cells or their cytokines are in development in treating Th17 cells-involved disorders. In this review, we summarize the up-to-date knowledge on roles of Th17 cells and their cytokines in GBS/EAN, as well potential approaches targeting Th17 cells and their cytokines as clinical applications. As Th17 cells produce different sets of pro-inflammatory cytokines and Th17-related cytokines are not exclusively produced by Th17 cells, targeting Th17 cell development may be superior to blocking a single Th17 cytokine to treat Th17 cells-involved disorders. Considering the essential role of retinoic acid-related orphan receptor ?T (ROR?T) and IL-23 in Th17 cell development, ROR?T inhibitors or IL-23 antagonists may provide better clinical efficacy in treating GBS/EAN.

Palavras-Chave: Guillain-Barré syndrome, T helper cell, Th17 cell, cytokine, experimental autoimmune neuritis

Imprenta: Expert Opinion on Therapeutic Targets, v. 20, n. 2, p. 209-222, 2015

Identificador do objeto digital: 10.1517/14728222.2016.1086751

Descritores: Guillain-Barre Syndrome - Cell ; Guillain-Barre Syndrome - Cytokines

Data de publicação: 2015

INDICADORES

ACESSO